Last reviewed · How we verify
II Consolidation HiDAraC
II Consolidation HiDAraC is a high-dose cytarabine (ara-C)-based chemotherapy regimen used as consolidation therapy in acute myeloid leukemia.
II Consolidation HiDAraC is a high-dose cytarabine (ara-C)-based chemotherapy regimen used as consolidation therapy in acute myeloid leukemia. Used for Acute myeloid leukemia (AML) consolidation therapy in first remission.
At a glance
| Generic name | II Consolidation HiDAraC |
|---|---|
| Also known as | - Cytosine arabinoside [Ara-C], - Cladribine |
| Sponsor | dr hab. n. med. Agnieszka Wierzbowska |
| Drug class | Nucleoside analog / Antimetabolite chemotherapy |
| Target | DNA synthesis (cytidine deaminase inhibition pathway) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HiDAraC delivers high-dose cytarabine, a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation. This consolidation phase follows induction therapy to eliminate residual leukemic cells and improve disease-free survival in AML patients who have achieved remission.
Approved indications
- Acute myeloid leukemia (AML) consolidation therapy in first remission
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Neurotoxicity (cerebellar syndrome, encephalopathy)
- Mucositis
- Infection
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- II Consolidation HiDAraC CI brief — competitive landscape report
- II Consolidation HiDAraC updates RSS · CI watch RSS
- dr hab. n. med. Agnieszka Wierzbowska portfolio CI